Biogen (NASDAQ:BIIB) is scheduled to post its quarterly earnings results before the market opens on Tuesday, April 24th. Analysts expect Biogen to post earnings of $5.89 per share for the quarter. Biogen has set its FY18 guidance at $24.20-25.20 EPS.
Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing analysts’ consensus estimates of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The company had revenue of $3.31 billion during the quarter, compared to the consensus estimate of $3.08 billion. During the same quarter last year, the firm posted $5.04 EPS. The company’s quarterly revenue was up 15.1% on a year-over-year basis. On average, analysts expect Biogen to post $25 EPS for the current fiscal year and $26 EPS for the next fiscal year.
NASDAQ BIIB opened at $263.02 on Friday. Biogen has a 12 month low of $244.28 and a 12 month high of $370.57. The stock has a market capitalization of $56,279.91, a price-to-earnings ratio of 12.06, a P/E/G ratio of 1.47 and a beta of 0.86. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.34.
A number of equities research analysts have commented on the company. BMO Capital Markets reiterated a “buy” rating on shares of Biogen in a research report on Thursday, January 25th. JPMorgan Chase reissued a “buy” rating on shares of Biogen in a research note on Thursday, February 8th. Canaccord Genuity boosted their price objective on Biogen from $340.00 to $350.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. Oppenheimer boosted their price objective on Biogen from $380.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, January 26th. Finally, Mizuho reissued a “buy” rating and issued a $433.00 price objective (up from $400.00) on shares of Biogen in a research note on Sunday, February 4th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twenty-one have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $366.49.
In related news, EVP Alfred Sandrock sold 259 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $290.83, for a total transaction of $75,324.97. Following the transaction, the executive vice president now directly owns 6,553 shares of the company’s stock, valued at approximately $1,905,808.99. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 2,296 shares of company stock worth $678,993. 0.25% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/22/biogen-biib-set-to-announce-earnings-on-tuesday.html.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.